Journal of veterinary internal medicine · 2026
Detection of neural autoantibodies in dogs with non-infectious inflammatory central nervous system disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heidemann Pernille L, Nilsson Christine, Schmidt Sandra G, Lattwein Erik, Agerholm Jørgen S, Blaabjerg Morten, Gredal Hanne
Аннотация
BACKGROUND: Easily obtainable biomarkers for non-infectious, inflammatory central nervous system (CNS) disorders in dogs are lacking.
HYPOTHESIS/OBJECTIVES: Dogs with non-infectious inflammatory CNS disorders might have specific neural autoantibodies in serum or cerebrospinal fluid (CSF), or both, discoverable by commercially available indirect immunofluorescence (IIF) assays.
ANIMALS: Dogs (n = 23) with non-infectious inflammatory CNS disorders, including meningoencephalomyelitis of unknown origin, were recruited from the University Hospital for Companion Animals (Copenhagen, Denmark).
METHODS: Using an exploratory, prospective study design, serum and CSF from dogs were investigated for specific neural autoantibodies with cell- and tissue-based IIF assays used to identify neural autoantibodies in humans.
RESULTS: Astrocytic autoantibodies against glial fibrillary acidic protein were present in 2 dogs, neuronal targeted autoantibodies against N-methyl-D-aspartate receptors (NMDAR) in 2 dogs, and tripartite motif-containing protein 46 in 1 dog. Additionally, autoantibodies toward myelin were suspected in 6 dogs and myelin-oligodendrocyte glycoprotein in 4 dogs. Autoantibodies against a neuronal surface structure were suspected in 1 dog but could not be further specified.
CONCLUSIONS AND CLINICAL IMPORTANCE: This study confirmed the presence of neural autoantibodies in several dogs with non-infectious inflammatory CNS disorders. The importance of both tissue- and cell-based assays (CBA) is emphasized by the fact that all specific autoantibodies apart from those targeting NMDAR were detected by tissue-based assays and then confirmed on cell-based assays (CBA).
HYPOTHESIS/OBJECTIVES: Dogs with non-infectious inflammatory CNS disorders might have specific neural autoantibodies in serum or cerebrospinal fluid (CSF), or both, discoverable by commercially available indirect immunofluorescence (IIF) assays.
ANIMALS: Dogs (n = 23) with non-infectious inflammatory CNS disorders, including meningoencephalomyelitis of unknown origin, were recruited from the University Hospital for Companion Animals (Copenhagen, Denmark).
METHODS: Using an exploratory, prospective study design, serum and CSF from dogs were investigated for specific neural autoantibodies with cell- and tissue-based IIF assays used to identify neural autoantibodies in humans.
RESULTS: Astrocytic autoantibodies against glial fibrillary acidic protein were present in 2 dogs, neuronal targeted autoantibodies against N-methyl-D-aspartate receptors (NMDAR) in 2 dogs, and tripartite motif-containing protein 46 in 1 dog. Additionally, autoantibodies toward myelin were suspected in 6 dogs and myelin-oligodendrocyte glycoprotein in 4 dogs. Autoantibodies against a neuronal surface structure were suspected in 1 dog but could not be further specified.
CONCLUSIONS AND CLINICAL IMPORTANCE: This study confirmed the presence of neural autoantibodies in several dogs with non-infectious inflammatory CNS disorders. The importance of both tissue- and cell-based assays (CBA) is emphasized by the fact that all specific autoantibodies apart from those targeting NMDAR were detected by tissue-based assays and then confirmed on cell-based assays (CBA).